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ABSTRACT
Implementing the most suitable treatment
strategies and making appropriate clinical
decisions about individuals with a first episode
of psychosis (FEP) is a complex and crucial task,
with relevant impact in illness outcome.
Treatment approaches in the early stages
should go beyond choosing the right
antipsychotic drug and should also address
tractable factors influencing the risk of relapse.
Effectiveness and likely metabolic and
endocrine disturbances differ among
second-generation antipsychotics (SGAs) and
should guide the choice of the first-line
treatment. Clinicians should be aware of the
high risk of cardiovascular morbidity and
mortality in schizophrenia patients, and
therefore monitoring weight and metabolic
changes across time is mandatory. Behavioral
and counseling interventions might be partly
effective in reducing weight gain and metabolic
disturbances. Ziprasidone and aripiprazole have
been described to be least commonly associated
with weight gain or metabolic changes. In
addition, some of the SGAs (risperidone,
amisulpride, and paliperidone) have been
associated with a significant increase of plasma
prolactin levels. Overall, in cases of FEP, there
should be a clear recommendation of using
lower doses of the antipsychotic medication. If
no or minimal clinical improvement is found
after 2 weeks of treatment, such patients may
benefit from a change or augmentation of
treatment. Clinicians should provide accurate
information to patients and relatives about the
high risk of relapse if antipsychotics are
discontinued, even if patients have been
symptom free and functionally recovered on
antipsychotic treatment for a lengthy period of
time.
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INTRODUCTION
Schizophrenia is a heterogeneous disorder with
a worldwide lifetime prevalence among adults
near 1% [1, 2]. The illness typically debuts in
late adolescence or young adulthood, can affect
personal, educational, social, and vocational
skills, and ranks among the 20 leading global
causes of disability worldwide [3]. Fortunately,
and based on recent evidence, the
conceptualization of illness outcome has
progressively evolved to a more optimistic and
inspiring perception of the illness with an
expectation of functional recovery from the
first episode [4, 5]. Imaging, clinical, and
cognitive longitudinal data do not support the
notion of a deteriorating course of the illness
[6–10], which consequently raises legitimate
expectations of living a normal life with
mental illness. Systematic reviews of outcome
studies have reported that 40–42% of people
with a first episode of psychosis (FEP) have a
good outcome [11, 12], although when more
stringent criteria of functional recovery are used
the rate drops to 13.5% long term [13].
Schizophrenia is unquestionably a
potentially disabling and severe mental illness;
however, an appropriate multidisciplinary and
integrated treatment approach from the first
episode can make a fulfilling and productive life
and the achievement of full potential possible
in spite of the limitations caused by the illness.
‘‘Recent-onset psychosis’’ has been previously
proposed as a more accurate term for referring
to individuals who have experienced a short
duration of illness (e.g., 2–5 years) [14]. By
contrast, the term ‘‘first episode psychosis’’
may include all subjects with a first treatment
contact, independently of the duration of the
symptoms. It has been stated that there is a
critical period of 2–5 years following onset of
psychosis during which future trajectories of
functional outcome may be set and when
interventions are likely to have a maximum
beneficial effect [15]. Recovery from a FEP has
come into focus as the main goal of any
treatment strategy. Many changeable factors
such as clinical (medication adherence,
treatment response) and psychotherapeutic
treatments, psychoeducation about the illness,
therapeutic alliance, support and recognition of
the needs of the people with a FEP and carers,
societal stigma, substance misuse, social and
family support, and physical health may affect
reaching this functional status [16]. Preventing
relapse in the early stages of disease has become
a major challenge due to its critical impact on
life-long functionality [17]. Non-adherence to
antipsychotic treatment and lack of insight into
the illness are very frequent in people with a
FEP [18]. Poor adherence to treatment is
associated with an increased rate of relapse
[19, 20]. Lack of insight promotes
non-adherence to medication and leads to a
poorer course of illness and functioning
[21–23]. Either because clinicians are not
always fully aware of these notions or because
these ideas are not well understood and
accepted by people in the early stages of the
illness, achieving and maintaining good
adherence to the prescribed treatment is a
major clinical issue.
Implementing the most suitable treatment
strategies and making appropriate clinical
decisions about individuals with a FEP is a
complex and crucial task, with associated
impact on illness outcome. These beneficial
effects seem to be more pronounced for those
patients who received the proper
comprehensive specialty care as early as
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possible in the course of the illness [24]. Early
detection and specialized intervention
programs have been extensively implemented
in the last decades for both individuals
suffering a FEP and their carers, offering a
wide range of pharmacological and
psychosocial interventions according to their
needs. Treatment approaches in the early
stages should go beyond choosing the right
antipsychotic drug to reduce acute psychotic
symptomatology and should also address
tractable factors influencing the risk of
relapse, with the greatest challenge of
accomplishing the long-term goal of
functional recovery (to achieve their best
premorbid functional level) in most of the
individuals with a FEP. These
conceptualizations and interventions should
also be shared and assumed by clinicians
dealing with FEP cases and working in
non-specialized mental health clinical settings.
A number of previous publications have
reviewed early intervention models or specific
issues (i.e., side effects of antipsychotics or
long-acting injectable antipsychotics) in the
treatment of people with a FEP. However, there
is a lack of updated reviews of the
pharmacological treatment of people with a
FEP, including use of novel antipsychotics that
help clinicians to choose and manage these
medications. This article aims to provide
clinicians with practical recommendations on
how best to manage people with a FEP. The
selection of an antipsychotic in the first stage
of the illness could be a highly relevant
decision, with a direct impact on adherence
to medication and acceptance of the illness,
and therefore influence the course and the
outcome of the illness. Advantages and
disadvantages of currently widely used drugs
to treat schizophrenia are outlined and
discussed.
METHODS
To obtain a fuller picture of the current best
treatment of people with a first episode of
non-affective psychosis a literature search
(1966 up to December 2015), using the
MEDLINE database, was conducted for
English-language published reviews,
meta-analyses, and clinical trials of first
generation antipsychotics (FGAs), second
generation antipsychotics (SGA), and newly
approved antipsychotics. The following
keywords were used: first episode psychosis,
recent-onset psychosis, schizophrenia,
non-affective psychosis, antipsychotics,
neuroleptics, effectiveness, and side effects.
The review is based upon studies carried out
with adults as well as children and adolescents.
We attempted to identify additional studies
through searches of the reference lists of
identified studies and reviews. Relevant data
obtained from articles based on chronic
schizophrenia samples were clearly identified
and separately reported to avoid any misleading
literature on first episode subjects.
This article is based on previously conducted
studies and does not encompass new studies of
human or animal subjects performed by any of
the authors.
AIMING FOR EFFICACY AND
EFFECTIVENESS
Balancing risks and benefits of antipsychotic
agents and, subsequently, increasing the
likelihood of adherence to treatment is the
real challenge in the treatment of FEP
individuals [25]. Table 1 summarizes the
advantages and disadvantages of the
antipsychotic agents discussed in this review.
The initial better tolerability of SGAs based on
the diminished emergence of extrapyramidal
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Table 1 Characteristics and proﬁles of antipsychotics used in the treatment of people with a ﬁrst-episode psychosis (FEP)
Antipsychotic Minimum
effective doses
in FEP
(mg/day)
Oral/long acting Advantages Disadvantages
Haloperidol
and other
FGAs
2 (haloperidol) Several agents have
long-acting
injection forms
Overall efﬁcacy in psychotic symptoms
Best level of evidence
High risk of EPS,
cognitive and
depressive symptoms
High risk of
hyperprolactinemia
Lower effectiveness
compared to SGAs
QTc prolongation
(Haloperidol and
other agents)
Olanzapine 5 Long-acting
injection form
available
High mid- and long-term effectiveness
compared to other antipsychotics
Low risk of hyperprolactinemia
Very high risk of weight
gain
Very high risk of lipid
and glucose
disturbances
Risk of sedation
Risperidone 2 Oral and long-acting
injection form
available
High mid- and long-term effectiveness
compared to other antipsychotics
Moderate risk of weight
gain and lipid
disturbances
High risk of
hyperprolactinemia
Risk of EPS compared
to other SGAs
Quetiapine 150 Oral Efﬁcacy in several symptomatic
domains
Low risk of hyperprolactinemia
Very high risk of weight
gain
Very high risk of lipid
and glucose
disturbances
Sedation
Probably lower
effectiveness
compared to other
SGAs
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symptoms and tardive dyskinesia has led to the
recommendation of SGAs as the first choice for
the treatment of a first episode of schizophrenia
in almost all international guidelines for early
psychosis [26, 27]. Presently it is widely
accepted that there is not an obvious
Table 1 continued
Antipsychotic Minimum
effective doses
in FEP
(mg/day)
Oral/long acting Advantages Disadvantages
Ziprasidone 80 Oral Lowest risk of weight gain and neutral
effect on glucose and lipids
Low risk of hyperprolactinemia
Probably lower
effectiveness
compared to other
SGAs
QT prolongation
Amisulpride 400 Oral Efﬁcacy and effectiveness High risk of
hyperprolactinemia
Limited evidence in ﬁrst
episode psychosis
Aripiprazol 10 Oral and long-acting
injection form
available
Low risk of weight gain and lipid and
glucose disturbances
Lowest risk of hyperprolactinemia
Low risk of sedation
Risk of akathisia
Paliperidone 3 Oral and long-acting
injection form
available
Low risk of sedation Moderate risk of weight
gain and lipid
disturbances
High risk of
hyperprolactinemia
Risk of EPS compared
to other SGAs
Limited evidence in ﬁrst
episode psychosis
Clozapine – Oral Greatest efﬁcacy and effectiveness
Efﬁcacy in people with a FEP that do
not respond to ﬁrst-line antipsychotic
treatment
Risk of weight gain and
lipid disturbances.
Agranulocytosis and
cardiac risk
Only for resistant
patients
Other SGA
agents
No data available from FEP samples
FGA ﬁrst generation antipsychotic, SGA second generation antipsychotic, EPS extrapyramidal symptoms
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difference between FGAs and SGAs in terms of
efficacy in decreasing the severity of positive
symptoms in schizophrenia [26]. However,
SGAs have shown higher treatment
effectiveness (lower rates of treatment
discontinuation) compared to FGAs (findings
primarily driven by haloperidol) in people with
a FEP [28–31]. This higher discontinuation rate
seems to be related not only to extrapyramidal
symptoms but also to some other disadvantages
of FGAs, as they may produce more secondary
negative and cognitive symptoms [32].
Additionally, these negative effects do not
seem to be homogeneous among different
medications within the SGA group [33, 34].
The response rate to an initial antipsychotic
trial is robust and thereafter the likelihood of
response decreases notably [35]. It is erroneous to
think that all SGAs are equally efficacious and
effective [35]. Differences among SGAs in terms of
effectiveness have turned out to be a topic of
increasing clinical interest, although
head-to-head comparisons between the different
SGAs are scarce in real-world clinical practice.
Crespo-Facorro and colleagues [34, 36, 37]
observed that individuals on quetiapine were
more likely to discontinue treatment after a first
episode due to insufficient efficacy compared to
those people treated with aripiprazole and
ziprasidone. A higher risk of treatment
discontinuation has been associated with
quetiapine treatment during the early phases of
treatment [18]. Kahn et al. [31] described no
difference between quetiapine and ziprasidone in
the rate of treatment discontinuation for any
cause, although discontinuation because of
insufficient efficacy was to some extent higher
with quetiapine (40%) compared with
ziprasidone (26%) recipients at 1 year.
Inadequate and transient dopamine D2 receptor
occupancy with quetiapine may lead to
insufficient antipsychotic efficacy [38, 39].
Additionally, ziprasidone has been reported to
be slightly less effective than other antipsychotics
in the treatment of people with a first episode of
psychosis [40]. In a sponsored investigation, there
were no significant differences between
olanzapine, risperidone, and quetiapine in
clinical efficacy or rate of treatment
discontinuation after 1 year [41]. Most of the
medium-term randomized studies have shown
similar rates of clinical response and all-cause
treatment discontinuation in people with a FEP
treated with other SGAs (risperidone, olanzapine,
ziprasidone, aripiprazole, amisulpride) [28, 31].
Robinson et al. [33] showed a similar efficacy and
effectiveness between aripiprazole and
risperidone for the acute treatment of
first-episode schizophrenia. Olanzapine might
lead to longer treatment maintenance than
haloperidol or ziprasidone in treatment-naı¨ve
people with a FEP [40]. Accordingly, Glick et al.
have reported in a metanalysis of medium and
long-term effectiveness that olanzapine and
risperidone appear to be the most effective
antipsychotics in the treatment of schizophrenia
and FEP [42].
In accordance with these findings, studies
based on samples of people with chronic
schizophrenia also pointed out that
quetiapine and ziprasidone could be
somewhat less effective than some other
widely used SGAs. Quetiapine has been
shown to be less effective than risperidone
(24% dropouts due to inefficacy in the
quetiapine group vs. 19% in the risperidone
group, RR: 1.26) or olanzapine (70% dropouts
due to any reason and 25% due to inefficacy in
quetiapine vs. 57% and 14%, respectively, in
the olanzapine group, RRs 1.22 and 1.8) [43].
When compared to olanzapine, subjects on
ziprasidone had a RR of 1.26 of stopping
medication due to any reason and of 1.57 of
due to medication inefficacy [44] Efficacy and
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effectiveness in chronic schizophrenia does not
seem to be significantly different among the
rest of the SGAs [45, 46].
Differences in effectiveness among SGAs
could help clinicians to avoid choosing the
lesser efficacious antipsychotics as first line
treatment.
CARDIOMETABOLIC SIDE EFFECTS:
SILENT LONG-TERM DAMAGE
In deciding among therapeutic options,
clinicians need to be aware of the differential
efficacy and safety of each agent. The choice by
clinicians of which antipsychotic drug to use for
first-line treatment of the illness is widely based
on the profile of side effects that may put
treatment alliance (at short-term) and physical
health (at medium- and long-term) at risk.
Drug-naı¨ve subjects are at a higher risk of
suffering antipsychotic side effects [47, 48]
Appearance of disturbing side effects and
concerns over the long-term damage
associated with antipsychotics are among the
key factors that make individuals discontinue
treatment once their acute symptoms have
subsided after a first episode of psychosis
[29, 49]. The risk of metabolic and endocrine
disturbances differs among SGA drugs.
Clinicians should be aware of the high risk of
premature mortality and lower life expectancy
in people with schizophrenia, the increase in
cardiovascular morbidity and mortality in FEP
being a critical factor for this risk status [50].
Therefore, prevention of the development of
cardiovascular risk factors (metabolic syndrome
and obesity, lifestyle, physical inactivity, and
unhealthy diet) from the first manifestation of
the illness is crucial in an integrative treatment
of psychosis [51]. Cardiovascular risk (weight or
metabolic indices), however, seems to be similar
in untreated FEP individuals and healthy
controls and noticeably increases after
first-time antipsychotic treatment [52].
Antipsychotic medication, in particular SGAs,
are related to marked weight gain and frequent
metabolic side effects, largely in young people
during early phases of the illness [53–55].
Weight gain may indirectly give rise to the
development of other components of metabolic
syndrome, and therefore be associated with
distress, lower functional outcome and
non-compliance with medication in
individuals with chronic schizophrenia
[56–58], and thus should ideally be prevented
from the first manifestation of the illness. Even
so, psychiatrists and patients should keep in
mind that cardiometabolic disturbances might
emerge without significant weight gain [59, 60].
Monitoring likely weight and metabolic
changes across time is mandatory in FEP
individuals who have just initiated
antipsychotic treatment.
Weight Gain
The first months of antipsychotic treatment
represent the critical period for changes in
weight [61, 62]. Longitudinal studies in
drug-naı¨ve subjects have shown that the
percentage of obese (body mass index (BMI)
[30) subjects increased from 5% to 32% and
the percentage of overweight rose up to 65% at
3 years after the initiation of treatment with
olanzapine, risperidone, or haloperidol [62].
Marked differences in likely weight gain exist
among the different SGAs. Of clinical relevance
is the fact that several reviews and studies have
shown that olanzapine and clozapine are
associated with a greater risk of weight gain
and higher percentage of extreme weight gain
([7%) and aripiprazole and ziprasidone have a
low risk of weight gain [52, 60, 63]. In a recent
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study in drug-naı¨ve individuals with a FEP,
aripiprazole and quetiapine showed a
significant increase in weight compared to
ziprasidone [54]. Studies on drug-naı¨ve
subjects are in agreement with this statement,
in particular during the first months of
treatment [45, 64, 65]. The EUFEST study
revealed that ziprasidone has a lesser effect on
weight gain than quetiapine and olanzapine
[31, 66]. Low doses of risperidone and
aripiprazole show a similar pattern of weight
gain during early phases of treatment in people
with a FEP [33, 54].
Accordingly, aripiprazole and ziprasidone
have shown lower liability for inducing weight
gain and metabolic adverse reactions than
olanzapine and risperidone in long-term
schizophrenia populations [64, 67–69].
Furthermore, several studies have shown that
switching from treatments with a high risk of
weight gain to ziprasidone [70, 71] or to
aripiprazole [72] is an effective strategy to
reduce weight and improve metabolic
outcomes in people with stable chronic
schizophrenia or schizoaffective disorder.
Finally, short-term, double-blind clinical trials
comparing ziprasidone with placebo parameters
[73, 74] or aripiprazole with placebo [75] in
people with chronic schizophrenia or
schizoaffective disorder have not found
significant differences in their effects on
metabolic variables.
The severity of weight increase, and therefore
fatty change, is correlated with hepatic and
cardiovascular toxicity. Thus, obesity is a risk
factor for nonalcoholic fatty liver disease
(NAFLD), which is the most common cause of
liver disease in Western countries [76]. Overall, it
has been described that 50% of people with a
BMI[30 may suffer NAFLD. In a recent study, it
has been demonstrated that over 25% of
individuals with a FEP will develop liver
steatosis after 3 years of treatment (Morlan
et al. 2015 submitted, personal
communication). Because of the link between
cardiometabolic risk, NAFLD, and antipsychotic
medication, early detection in clinical practice of
NAFLD development, based on non-invasive
techniques, could be worthy of consideration,
as these subjects should be considered for liver
disease treatment and for monitoring and
potential treatment of underlying
cardiovascular risk factors [77]. It has been
observed that individuals treated with
olanzapine who gained a substantial amount of
weight manifested significantly lower heart rate
variability (a marker of high cardiovascular risk)
[78].
In addition to physical disturbances, weight
stigmatization and discrimination lead to
important psychological stress that increases
the risk for depression, low self-esteem, and
body dissatisfaction in people with
schizophrenia [79]. In the long term, weight
gain may lead to poorer social and functional
outcomes [80] and weight loss is linked to an
improvement in social functioning [81] in
people with schizophrenia.
Behavioral and counseling interventions
including smoking cessation, dietary measures,
and exercise might be partly effective in
reducing weight gain and metabolic
disturbances in early stages of treatment
[82–84]. Nonetheless, the benefits of these
lifestyle interventions do not seem to persist
across time [85]. The preferential use of or
switching to medications with a lower risk of
weight and/or metabolic abnormalities is
recommended [86].
Glucose Metabolism
The risk of glucose intolerance and diabetes
associated with antipsychotic treatments seems
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to be increased in younger subjects [87]. After
3 years of antipsychotic treatment, insulin
plasma levels and the HOMA index tend to
increase in FEP individuals [62]. Olanzapine,
clozapine, and quetiapine have been associated
with more prevalent hyperglycemia
independently of body mass in both
drug-naı¨ve [88] and chronic schizophrenia
individuals [89, 90]. Higher levels of insulin
and insulin resistance were associated with
olanzapine treatment in patients with FEP or
schizophrenia and in healthy normal-weight
men [31, 91, 92]. Quetiapine treatment has also
been shown to increase the risk of triglycerides
to HDL-C ratio (a marker of insulin resistance)
in FEP [50]. A critical factor to bear in mind by
clinicians is the fact that type 2 diabetes might
have an onset a median of 4 years after first
antipsychotic treatment, although subjects on
olanzapine had a shorter time to diabetes onset
[88]. It has also been reported that olanzapine
discontinuers did not have an increased risk of
diabetes [88]. Higher antipsychotic dosages and
male sex seem to be related to an increased risk
for diabetes. Due to the close association
between metabolic effects and the greater risk
of diabetes, pre-diabetes or type 2 diabetes
should be prevented or postponed by choosing
as a first choice an antipsychotic with a lower
cardiometabolic burden.
Lipid Metabolism
After 3 years of antipsychotic treatment, a high
proportion of FEP individuals may have been
exposed to high plasma total triglyceride
concentrations (up to 23%), low levels of
HDL-C (23%), and a high total cholesterol/
HDL-C ratio (29%) [62]. Olanzapine and
quetiapine have shown the greatest effect on
lipid status, whereas aripiprazole and
ziprasidone have produced the lowest effects
on lipid levels in both FEP and chronic
schizophrenia populations [32, 93]. Our group
has described that after 12 weeks of treatment
ziprasidone has a neutral effect on fasting
plasma lipids and glucose [54]. Importantly,
increases in dyslipidemia and triglycerides have
been shown to be meaningfully associated with
olanzapine treatment independent of weight
gain in both FEP and chronic schizophrenia
[94, 95]. In a recent study, Robinson and
colleagues (2015) observed that cholesterol
and LDL-C levels, but not triglycerides and
HDL-C, were significantly less affected in
individuals on aripiprazole compared to
risperidone-treated FEP patients [33].
ADDITIONAL RELEVANT ADVERSE
EVENTS
Prolactin-Related Side Effects
Hyperprolactinemia is considered to be a
disturbing adverse effect of antipsychotic
medication, although recent investigations
have described that it might be also a
pre-existing or stress-related condition, since it
has been described in antipsychotic-naı¨ve
people with FEP [96–99] and in subjects with
an at-risk mental state [96]. Antipsychotic
medications differ in their propensity to
induce hyperprolactinemia (for a review see
Peuskens et al. [100]). Most FGAs have been
associated with a pronounced elevation of
prolactin levels in the treatment of FEP
[30, 101], but some investigations in FEP have
described no significant prolactin changes at
long term associated with haloperidol
treatment [31, 98]. Some of the SGAs are
considered prolactin-sparing antipsychotics
and quetiapine, ziprasidone, olanzapine,
clozapine, and aripiprazole are less likely to
induce sustained hyperprolactinemia
Neurol Ther (2016) 5:105–130 113
[31, 39, 54, 98, 102], but others have been
associated with significant increases in plasma
prolactin levels, and thus are considered to be
prolactin-elevating antipsychotics –
risperidone, amisulpride, and paliperidone
[31, 101]. Nonetheless, clinicians should be
fully aware that 40% of the subjects on
prolactin-sparing antipsychotics might exhibit
hyperprolactinemia. Plasma prolactin level
elevations with antipsychotic drugs are
generally dose dependent [100].
Many patients with elevated prolactin levels
are asymptomatic, and others may not report
symptoms unless specifically questioned [103].
Sustained elevation of prolactin may cause
amenorrhea, galactorrhea, hirsutism,
gynecomastia, impotence, loss of libido, and
infertility in the short term. Long term
hypogonadism due to hyperprolactinemia may
lead to osteoporosis and hip fracture [100]. The
expected utility of switching to or adding
aripiprazole to rapidly decrease elevated
prolactin levels induced by prolactin-elevating
antipsychotics has been described in samples of
patients with chronic schizophrenia [104, 105].
Antipsychotic-associated hyperprolactinemia
is the most common cause of elevations in
prolactin levels in individuals with
schizophrenia, but additional appropriate
investigations may also be warranted for those
individuals with persistently elevated prolactin
levels [106]. Clinicians should consider
reducing the antipsychotic dosage or
switching to an antipsychotic drug with a
lower potential to elevate prolactin in cases of
hyperprolactinemia.
Sedation
Sedation is a common and unpleasant adverse
effect of both FGAs and SGAs [18], with young
subjects seemingly more affected by
somnolence and hypersomnia than older
adults [107, 108]. Given that sedation-related
side effects may particularly cause discomfort
and daytime dysfunction, this effect may lead
to patients becoming non-adherent to
treatment in patients with schizohrenia [109].
Some clinicians may regard sedation as a
helpful effect during an acute episode for
addressing symptoms such as insomnia and
agitation and may use antipsychotics with
sedative effects, antipsychotic combinations or
higher doses in order to obtain sedation.
However, in a phase-specific treatment,
sedation may no longer be needed and should
be closely monitored and prevented, including
the reduction of antipsychotic doses, avoiding
polypharmacy, or switching the antipsychotic
[110]. Leutch et al. showed evidence that
clozapine and chlorpromazine are associated
with higher sedation, and amisulpride and
paliperidone certainly produce less sedation in
the treatment of individuals with schizophrenia
[111].
OTHER KEYSTONE ASPECTS
IN THE TREATMENT
OF FIRST-EPISODE INDIVIDUALS
What are the Recommended Doses at Early
Phases?
Young people suffering from a first episode of
psychosis seem to be highly responsive to low
doses of antipsychotics and more susceptible to
extrapyramidal side effects and to acute weight
gain [112, 113]. In the last few decades,
chlorpromazine doses in people with
schizophrenia and other psychoses have been
gradually reduced and this has probably led to
less extrapyramidal side effects [114]. A clear
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limitation when establishing the lower effective
antipsychotic dose in the FEP population is that
available dose-equivaleny methods for
antipsychotics are not applicable to FEP [115].
Additionally, people with a FEP are more likely
to respond to lower doses of antipsychotic
medications and treatment should be started
at the lower half of the recommended dosage
range for multiple episodes (300–500 mg
chlorpromazine equivalents per day) [116].
There is a clear recommendation for using
lower doses of antipsychotic medications in
cases of FEP [27, 116, 117]. Previous studies
assessing the efficacy of antipsychotics in FEP
have evaluated the efficacy of lower doses. The
mean modal doses of risperidone have ranged
from 2.4 to 4 mg/day [41, 101, 118, 119], and of
olanzapine from 9.1 to 12.6 mg/day
[31, 41, 120]. Minimum effective doses of
2 mg of haloperidol [121] or lower and 2 mg of
risperidone [120] have been previously reported
in FEP. As an example, in our cohort, FEP was
effectively treated with initial modal doses at
6 weeks of 5 mg of haloperidol (range
3–9 mg/day), 4 mg of risperidone
(3–6 mg/day), 15 mg of olanzapine
(5–20 mg/day) [49], 15 mg of aripiprazole
(5–20 mg/day), 80 mg of ziprasidone
(40–160 mg/day), or 300 mg of quetiapine
(100–600 mg/day) [36]. In a recent
investigation Robinson et al. used mean daily
doses of 14.8 mg for aripiprazole and 3.2 mg for
risperidone [33]. Even with a ‘‘start low, go
slow’’ model, given that people with a FEP
require low doses, they may be treated with
effective doses from the first week and the
antipsychotic rapid titration should allow
adjusting doses to avoid side effects.
Although doses may be reasonably increased
within the therapeutic range if a clinical
response is not obtained, an increase in the
antipsychotic dose is less likely to be successful
in FEP, so using high antipsychotic doses is
discouraged [35].
It has been suggested that the long-term use
of antipsychotics may lead to a dopaminergic
supersensitivity state, caused by an
upregulation of the dopamine receptors [122]
that would predispose patients with psychosis
who receive longer and higher doses to relapse.
However, studies that have tried to test this
theory have failed to prove it, as they did not
find differences according to medication type
withdrawn or tapered [123].
How Long Should Clinicians Wait Before
Switching an Initiated Antipsychotic Drug
in Cases of Lack of Efficacy?
According to international treatment
guidelines, there is uncertainty about the
recommended time clinicians should wait
before switching medication, suggesting an
initial trial of ‘‘appropriate doses’’ of
antipsychotics from 2 to 6 weeks according to
current guidelines [124, 125]. The risk-benefit
assessment clearly favors switching
antipsychotics when a given medication is
clearly ineffective. Nevertheless, clinicians,
before making the decision to switch, should
ensure that treatment with the pre-switch
antipsychotic was optimized in terms of
adherence and dose [126]. In a recent
meta-analysis, Samara et al. reported that
people with schizophrenia who did not even
minimally improve at week 2 of treatment with
sufficiently high doses are unlikely to respond
later and therefore may benefit from a change
or augmentation of treatment. Ninety percent
of subjects who do not show a minimal
response (20% reduction in the PANSS/BPRS
score) at the 2-week assessment will not show
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clinical improvement at week 6 [127]. Although
the application of these results seems to be more
appropriate for people who are not in their first
episode of schizophrenia, they emphasize the
need for a rapid titration model in order to
achieve an adequate dose during the first days
of treatment. Additionally, clinicians dealing
with FEP individuals should be fully aware of
the necessity of switching or implementing
augmentation treatment strategies early in the
course of the antipsychotic treatment to avoid
unnecessary long-term exposure to an
antipsychotic that is very unlikely to be
helpful. Lack of clinical efficacy is among the
reasons that might prompt people with an FEP
to treatment discontinuation [19]. Strategies for
switching have been previously poorly studied
in an attempt to make an accurate
recommendation, but the future results of two
ongoing trials, SWITCH and OPTiMiSE, should
help decision making and provide a basis for
clinical guidelines. In a previous finding, Agid
et al. [128] described only a 20% responsiveness
among subjects who did not respond to the
first-line antipsychotic drug, whereas the
efficacy rate of clozapine in these
nonresponsive subjects was 75%; therefore
early after a lack of response, a second
antipsychotic trial and then the use of
clozapine may be indicated when other issues
such as adherence or co-morbidity have been
addressed [27, 125].
Likely problems in switching antipsychotics
in the treatment of schizophrenia such as the
risk of discontinuation reactions and the
re-emergence of psychotic symptoms have
been traditionally described [129, 130]. Thus,
overall patients should be monitored carefully
throughout the switch procedure for any
discontinuation effects or new side effects
[131, 132]. More frequent contacts might be
needed during the switching process in order to
reassure the patient and to monitor for side
effects and discontinuation problems
[133, 134].
As with individuals with several episodes,
using antipsychotic polypharmacy is
discouraged due to a lack of proven efficacy
and a higher risk of side effects [125, 135].
Importantly, co-morbid symptoms such as
depression, anxiety, suicide risk, and substance
misuse must be correctly diagnosed and treated
in order to avoid early refractoriness, lack of
remission, and relapse [27, 125]. Subjects who
not respond to the first antipsychotic trial after
a few weeks have a low response rate thereafter.
Addressing co-morbidity must include not only
choosing the appropriate antipsychotic
medication but also offering adequate
psychosocial interventions such as cognitive
behavior therapy (CBT) or treating associated
problems such as substance abuse [136, 137].
CBT has been reported as a useful treatment for
schizophrenia in several reviews [138–141],
particularly in the treatment of persistent
positive symptoms as part of a combined
therapy. This has led to the inclusion of CBT
into services and recommendations of
treatment guidelines for people suffering
psychotic disorders, including a FEP [27, 125].
Moreover, CBT seems to be helpful in
improving other symptoms such as negative
symptoms, functioning, mood, and social
anxiety [142–145]. However, Jauhar et al.
described in a meta-analysis of CBT
effectiveness for symptoms of schizophrenia
that pooled effect sizes were in the ‘‘small’’
range for all the classes of symptoms considered
(pooled effect size of -0.33 for overall
symptoms; -0.25 for positive symptoms;
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negative sign favors CBT) [146]. Previous recent
meta-analyses by Wykes et al. had described
higher levels of effectiveness that were in any
case modest (i.e., pooled effect size of -0.37 for
positive symptoms, pooled effect size of -0.44
for negative symptoms) [147]. With regard to
substance misuse, integrated CBT and
motivational interviewing have been used
with the aim of reducing the use of substances
and reduce subsequent relapses in a FEP;
however, results of these interventions are not
clearly consistent [137, 148–150]. Although
there are some ongoing trials evaluating the
specific efficacy of CBT and motivational
interviewing in reducing the use of some
substances such as cannabis [151], it is possible
that the benefits of these psychosocial
interventions are best reflected in their effects
on symptomatic outcomes rather than in a
reduction of substance use or relapse
prevention, and therefore the appropriate
strategy may be to address associated problems
rather than the substance use per se [137]. CBT
for psychosis (CBTp) cannot be considered as a
global brand because not all approaches are the
same. It is now highly recommended that
choosing the most appropriate CBTp should
take into account patient-defined goals and
critical targets and the types of individuals
who can benefit from therapy [152].
How Long Should Patients be Maintained
on Antipsychotic Medication After
Recovering from a First Episode?
In clinical practice, due to the lack of insight
into the prophylactic effects of drugs,
emergence of disturbing side effects, and
concerns over the long-term harm associated
with antipsychotics, it is unlikely that patients
will accept an indefinite treatment after a single
episode of psychosis [20]. However, stopping
antipsychotic medication has been repeatedly
demonstrated as the biggest predictor of relapse
after a first episode [153–155]. Wunderink et al.
[156], exploring people that remitted after a
FEP, observed that relapse rates were two times
higher in individuals who gradually tapered or
discontinued medication and only 20% of
subjects could be successfully discontinued.
Strikingly, those patients with an earlier
reduction or discontinuation treatment
strategy appear to have long-term functional
gains compared with individuals who
maintained treatment [157, 158]. In a recent
investigation, Mayoral-van Son et al. [20]
described a high risk of symptom recurrence
after antipsychotic treatment discontinuation
in individuals who had accomplished a
functional recovery after a single psychotic
episode. Moreover, those relapsed individuals
had a greater severity of symptoms and lower
functional status after 3 years. The profile of
individuals who would benefit from treatment
discontinuation, and the optimal duration of
prophylactic antipsychotic medication remain
unclear. The lowest effective-dose regimen is
highly recommended [20, 154] and a trial off
antipsychotic medication is not to be
recommended [159]. Clinicians should provide
accurate information to people with a FEP (and
relatives) about the fact that even if they have
been symptom free and functionally recovered
on antipsychotic treatment, the risk of relapse is
still likely to be high if antipsychotics are
discontinued [160]. Despite these clear
statements, numerous individuals may still be
disposed to discontinue medication after
recovering from their single episode of
psychosis and, therefore, a planned
medication withdrawal strategy with a
systematic follow-up should be established in
first-episode programs to prevent unrestrained
treatment discontinuation.
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What Else Can Clinicians do to Increase
Treatment Adherence during Early Phases
of the Illness?
Independent of the initial high response rate
after a FEP, during follow-up of the illness, the
relapse rates are high, being up to 83% 5 years
after the FEP [153]. Persistent substance use
disorder, carer criticism, poorer premorbid
adjustment, and, particularly, medication
nonadherence (a fourfold risk) may
significantly increase the risk for relapse in FEP
[161]. In a previous report analyzing a
subsample of 140 first episode individuals, we
observed a similar relapse rate of 65% at 3 years
after the first break of the illness, being
adherence to antipsychotic treatment the only
significant predictor for relapse [155]. Therefore,
in order to prevent relapse, the best way would
be to improve adherence and to reduce other
avoidable risk factors such as substance use or
carer criticism. A basic strategy that may help
clinicians improve their patients’ adherence
includes improving prescriber-patient
communication. The clinician should listen
the patient, understand his or her perspective,
beliefs and concerns about the illness and
treatment, and should provide information
regarding potential effectiveness, side effects,
and formulations in order to get the patient
involved in decisions about their medications
[162]. The use of psychosocial treatments,
including psychoeducational interventions,
CBT, and individual and family interventions,
may specifically improve adherence and must
be offered in combination with antipsychotic
treatment in order to prevent relapses in
patients with a FEP [163]. Finally, after the
evaluation of adherence and associated risks
and the provision of adequate medication,
psychoeducation and long-acting
injectable (LAI) antipsychotics should be
offered in order to improve outcome in
selected subjects [164, 165]. The use of LAI
antipsychotics has been traditionally restricted
to people who are noncompliant and who have
a history of multiple relapses, and FEP is rarely
treated with depot medications [166]. Early
introduction of LAI therapy in FEP has been
associated with a short-term adherence benefit
[167]. However, subsequent follow-up of the
same cohort did not reveal differences between
patients treated with LAI therapy and patients
with oral antipsychotics in time to initial
non-adherence at 104 weeks [168]. Although
more well designed, randomized, controlled
clinical trials using SGA LAIs exploring
effectiveness and likely long-term side effects
are warranted, LAIs should be given due
consideration in early phases treatment of
based on their benefits with regard to
adherence [169]. In a recent review of the
literature on the use of LAIs in first-episode
and early schizophrenia, Taylor and Ng
concluded that LAIs are useful in reducing
symptom severity and the risk of relapse,
particularly if they voluntary accept LAI
therapy [170]. Ironically, clinicians are often
reluctant to offer LAIs in early phases and tend
to overestimate potential objections by patients
[171].
After obtaining a clinical response,
accomplishing symptomatic and functional
remission is one of the major objectives of
treating individuals with a FEP, with a final
objective of functional recovery. In 2005, the
Remission in Schizophrenia Working Group
published the most widely accepted criteria to
define remission in schizophrenia [172]. This
concept includes the remission of positive
psychotic, disorganized, and negative
symptoms to a severity of mild or less, but
also a minimum duration time for this
remission of 6 months, and has been used in
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FEP. Rates of remission vary widely in different
studies and most of them do not provide
duration criteria [173]. As an example, after a
1-year follow-up, only 31% of the initial
subjects enrolled in the PAFIP program
achieved remission [174], in particular due to
persistence of negative symptoms or to relapse
in the last 6 months, which seem to be related
to duration of untreated psychosis and
premorbid functioning. Remission is closely
related to functional recovery, although
symptomatic remission rates tend to exceed
functional recovery rates [173]. The best ways to
achieve remission after improving initial
symptoms seem to be preventing relapses and
also detecting and treating secondary negative
symptoms as early as possible. Additionally,
vocational interventions have been recognized
to be beneficial to achieve better functional
outcomes [175].
What Can we do to Help and Support
Families and Caregivers of Individuals
Dealing with a First Episode?
One of the main objectives of FEP programs and
early intervention services is to engage with
both people with psychosis and their family and
to facilitate support. However, until recently,
most of the effort has gone into studying,
recognizing, and reducing expressed emotion
(EE) and its components – critical comments
(CC) and emotional over-involvement (EOI) –
due to its potential prediction of relapse and
symptom exacerbation in schizophrenia. Given
that a large majority of people during their FEP
live at home with their families, these informal
caregivers are affected by a
stress-appraisal-coping framework [176]. This
would mean that the extent to which the
stressors are related to the relative’s or
caregiver’s negative health is related to his/her
appraisal (or subjective evaluation) of the
stressor and his/her ability to cope with them.
Apart from family interventions, basically
aimed at preventing or reducing relapses,
psychoeducation and support groups have been
developed to improve the experience of caring
for people with mental illness, and particularly
may be recommended to families and caregivers
of people with FEP and severe mental disorders
[177]. The role of FEP programs and early
intervention services is to detect the needs of
the families and caregivers and give sustained
appropriate communication and support, in
order to improve their experience of caring and
reduce associated stress.
New Second Generation Antipsychotics:
Future Options for First-episode Treatment
Although the antidopaminergic mechanism
(need for D2R blockade) is still essential in the
development of new antipsychotics, the
investigation of new atypical antipsychotics
has focused on either compounds with a
broader spectrum of clinical benefits through
dual dopaminergic and serotoninergic
properties – ‘‘serotonin-dopamine activity
modulators’’– (e.g., partial agonism of D2R with
enhanced affinity for specific serotonin receptor
analog of aripiprazole) or exploiting less
examined mechanisms (e.g., cholinergic,
histaminergic, GABAergic, modulation of
glutamate); for a review see Zajdel et al. [178].
Brexpiprazole, with structure, properties and
uses that are most similar to those of
aripiprazole, has recently exhibited good
tolerability, with a lower incidence of akathisia
than aripiprazole [179]. Initial animal studies
with cariprazine, a potent D3/D2 receptor
partial agonist with favored binding to D3
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receptors, seem to point out it could be a better
treatment option for patients with persistent
and predominant negative symptoms [180].
The long half-life of cariprazine’s principal
active metabolites and the steady-state levels
of cariprazine and metabolites within 4 weeks
are pharmacological characteristics that may
minimize the impact of missing doses on
plasma levels [181]. Significant improvement
in hostility has been also observed in
cariprazine- versus placebo-treated patients
[182]. Iloperidone shares a high affinity for
both D2 and 5HT2A receptors, with a unique
receptor-binding profile that includes a very
strong affinity for the noradrenergic alpha 1
(NEa1) receptor [183]. It is a well-tolerated
antipsychotic with a very low propensity to
cause either akathisia or antipsychotic-induced
extrapyramidal symptoms [184]. Lurasidone
exerts a potent antagonism toward the
dopamine D2, and the 5-hydroxytryptamine
(5-HT, serotonin) receptors: 5-HT2A and 5-HT7
[185]. Apparently lurasidone is less efficacious
than clozapine, risperidone, paliperidone,
olanzapine, and amisulpride, with a lower risk
of sedation and body mass increase [111, 186].
However, subjects treated with lurasidone
exhibited higher rates of akathisia,
parkinsonism, and hyperprolactinemia
compared to several other atypical
antipsychotics. To the best of our knowledge
none of the above new SGAs have been studied
in first-episode cohorts to date.
CONCLUSION
Treating individuals with a FEP is a complex and
crucial task, with important impact on illness
outcome. The selection of antipsychotic at the
first episode of the illness is an important
decision, with a direct impact on adherence to
medication and acceptance of the illness, and
therefore influencing the course and the
outcome of the illness. It is erroneous to think
that all SGAs are equal in terms of effectiveness
and risk of side effects. Clinicians need to be
aware of the potential efficacy and safety of
each antipsychotic in order to choose the most
appropriate drug for the needs of individual
patients. Monitoring likely weight and
metabolic changes across time is mandatory in
individuals who have just initiated
antipsychotic treatment. Intervention
strategies in early stages should certainly go
beyond choosing the proper antipsychotic and
should also tackle tractable factors influencing
adherence to treatment and risk of relapse, with
the aim of accomplishing the long-term goal of
functional recovery. Clinicians should provide
accurate information to patients with a FEP and
their relatives about the risk of relapse if
antipsychotics are discontinued, and assess the
needs of the families and caregivers in giving
support in order to improve their experience of
caring and reduce associated stress.
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